Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease

BACKGROUND: Fingolimod is the first oral immunomodulatory therapy approved for highly active relapsing remitting multiple sclerosis. Based on the distribution pattern of fingolimod interacting sphingosine-1-phosphat receptors in organism including immune system and cardiovascular system clinical mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Katja, Schrötter, Hagen, Halank, Michael, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055797/
https://www.ncbi.nlm.nih.gov/pubmed/24906818
http://dx.doi.org/10.1186/1471-2377-14-126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055797/
https://www.ncbi.nlm.nih.gov/pubmed/24906818
http://dx.doi.org/10.1186/1471-2377-14-126

Ejemplares similares